SAGE Therapeutics, Inc.(NASDAQ : SAGE)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading SAGE News...
Health Technology » Pharmaceuticals Other
|VRX||Valeant Pharmaceuticals International, Inc.||1.56%||16.61||10.2%||$221.79m|
|SHPG||Shire PLC Sponsored ADR||2.05%||184.71||0.3%||$192.76m|
|PRGO||Perrigo Co. Plc||0.06%||84.14||4.3%||$133.97m|
|ENDP||Endo International Plc||4.54%||13.48||9.0%||$97.37m|
|PRXL||PAREXEL International Corporation||-0.15%||65.84||7.5%||$84.88m|
|UTHR||United Therapeutics Corporation||-2.38%||143.48||13.5%||$80.75m|
|JAZZ||Jazz Pharmaceuticals Plc||0.32%||135.38||2.3%||$69.33m|
|ICPT||Intercept Pharmaceuticals, Inc.||-8.01%||112.96||21.9%||$60.63m|
|SAGE||SAGE Therapeutics, Inc.||-0.67%||61.52||12.1%||$48.52m|
|GWPH||GW Pharmaceuticals PLC Sponsored ADR||-1.40%||123.42||10.9%||$47.41m|
|PTLA||Portola Pharmaceuticals, Inc.||-2.58%||31.31||8.8%||$39.59m|
|HZNP||Horizon Pharma plc||0.12%||17.06||11.1%||$38.87m|
|SGYP||Synergy Pharmaceuticals, Inc.||-5.69%||5.33||16.1%||$38.44m|
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.